Evidence map›Paper›PMID 36613562›Full record

ArticleInternational journal of molecular sciences2022

Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.

Sonia Domingos-Pereira, Karthik Sathiyanadan, Lenka Polak, Jacques-Antoine Haefliger, Martina Schmittnaegel, Carola H Ries, Patrice Jichlinski, Beat Roth, Laurent Derré, Denise Nardelli-Haefliger

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sonia Domingos-PereiraDepartment of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.
Karthik SathiyanadanDepartment of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.
Lenka PolakDepartment of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.
Jacques-Antoine HaefligerDepartment of Medicine, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.ORCID 0000-0003-2732-1667
Martina SchmittnaegelRoche Innovation Center Munich, Pharma Research and Early Development, 82377 Penzberg, Germany.
Carola H RiesRoche Innovation Center Munich, Pharma Research and Early Development, 82377 Penzberg, Germany.
Patrice JichlinskiDepartment of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.
Beat RothDepartment of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.
Laurent DerréDepartment of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.ORCID 0000-0002-3403-161X
Denise Nardelli-HaefligerDepartment of Urology, Lausanne University Hospital, University of Lausanne, 1010 Lausanne, Switzerland.
University of Lausanne · CHRoche Pharma AG (Germany) · DE

Funding

Roche (Germany) NASwiss Cancer League KFS 4103022017 and KFS 3796022016Swiss National Science Foundation 32153201
6 · The paper itself

Abstract

Bacillus Calmette-Guérin (BCG) instillations for the treatment of non-muscle-invasive bladder cancer patients can result in significant side effects and treatment failure. Immune checkpoint blockade and/or decreasing tumor-infiltrating myeloid suppressor cells may be alternative or complementary treatments. Here, we have characterized immune cell infiltration and chemoattractant molecules in mouse orthotopic MB49 bladder tumors. Our data show a 100-fold increase in CD45

Indexed as

B7-H1 AntigenUrinary Bladder NeoplasmsAnimalsCell Line, TumorChemokinesMiceMyeloid CellsTumor MicroenvironmentUrinary BladderB7-H1 AntigenChemokineschemokine expressionchemokine-targetingimmune infiltrationnon-muscle-invasive bladder cancerorthotopic MB49-bladder model

Identifiers

PMID36613562
PMCPMC9820528
OpenAlexW4313583862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.